Clinical Report: New SUNY Eye Biobank
Overview
The SUNY College of Optometry has received $1.5 million to establish the SUNY Eye Biobank. This initiative will integrate clinical data, ocular imaging, and biological information to explore connections between vision, aging, and neurological health.
Background
The establishment of the SUNY Eye Biobank aims to facilitate research on age-related neurological and visual disorders. By leveraging the eye's unique ability to provide insights into broader neurological health, this biobank will support research efforts.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
- The SUNY Eye Biobank is the first resource of its kind in the US, focusing on age-related neurological and visual disorders.
- It will combine clinical data, ocular imaging, and biological information for research purposes.
- The initiative is led by Dr. Jose-Manuel Alonso, a professor at SUNY Optometry.
- The biobank aims to investigate the links between vision, aging, and neurological disease.
- This project is part of the SUNY Brain Institute's focus on age-related brain disorders.
Clinical Implications
The SUNY Eye Biobank may provide resources for researchers studying the intersection of vision and neurological health.
Conclusion
The establishment of the SUNY Eye Biobank is intended to advance research on age-related neurological and visual disorders.
Related Resources & Content
- SUNY College of Optometry, Source, 2023 -- New SUNY Eye Biobank
- Ophthalmology Management — Eye Banks Doing More for Surgeons
- the pathologist — Bank With Us
- the pathologist — Improved Outlook for Eye Cancer Diagnostics
- corneal physician — Examining Whats New in Eye Banking
- Eye Banks Doing More for Surgeons
- Bank With Us
- Improved Outlook for Eye Cancer Diagnostics
- Best Practices for Using Human Eye Tissue in Research
- Preferred Practice Pattern® Guidelines: Ophthalmology
- Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
